Evidence map›Paper›PMID 40906326›Full record

Observational studyClinical and experimental nephrology2025

Combined effect of hyperhomocysteinemia and mild-to-moderate chronic kidney disease on mortality and cardiovascular events in the Japanese general population: the Yamagata (Takahata) study.

Tomohiro Takehara, Yoichiro Otaki, Kai Matsuo, Tetsuro Goto, Yuzuka Kuramasu, Takaya Suzuki, Masahiro Miyata, Takaaki Nawano, Eri Matsuki, Sayumi Watanabe and 6 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tomohiro TakeharaDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Yoichiro OtakiDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan. y-otaki@med.id.yamagata-u.ac.jp.ORCID http://orcid.org/0000-0001-7859-1427
Kai MatsuoDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Tetsuro GotoDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Yuzuka KuramasuDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Takaya SuzukiDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Masahiro MiyataDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Takaaki NawanoDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Eri MatsukiDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Sayumi WatanabeDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Keita KameiDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Natsuko SuzukiDepartment of Public Health and Hygiene, Yamagata University School of Medicine, Yamagata, Japan.
Kazunobu IchikawaDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Tetsu WatanabeDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Tsuneo KontaDepartment of Public Health and Hygiene, Yamagata University School of Medicine, Yamagata, Japan.
Masafumi WatanabeDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperhomocysteinemia (HHcy) and chronic kidney disease (CKD) are risk factors for cardiovascular events and all-cause mortality. Although their coexistence may further amplify these risks, few studies have evaluated this association, particularly in patients with mild-to-moderate CKD.

methodsIn this retrospective analysis of prospective observational cohort, we analyzed data from 3,377 residents aged ≥ 40 years living in Takahata, Japan. Baseline data were collected between 2004 and 2006. Eligibility for inclusion required an estimated GFR of ≥ 30 mL/min/1.73 m

resultsMedian follow-up period was 18.6 years (interquartile range: 17.2-19.3). The Kaplan-Meier analyses revealed that individuals with both HHcy and CKD had the highest incidence of all-cause mortality and cardiovascular events (log-rank p < 0.001 for both). After adjusting for cardiovascular risk factors, this group remained at the highest risk, with hazard ratios of 2.49 and 2.11 and 95% confidence intervals of 2.00-3.10 and 1.32-3.38 for all-cause mortality and cardiovascular events, respectively.

conclusionIn the Japanese general population aged ≥ 40 years, the coexistence of HHcy and mild-to-moderate CKD was associated with a significantly higher risk of all-cause mortality and cardiovascular events than either condition alone.

Indexed as

Cardiovascular DiseasesHyperhomocysteinemiaRenal Insufficiency, ChronicAdultAgedEast Asian PeopleFemaleGlomerular Filtration RateHumansIncidenceJapanKaplan-Meier EstimateMaleMiddle AgedRetrospective StudiesRisk FactorsAll-cause mortalityCardiovascular eventsChronic kidney diseaseGeneral populationHyperhomocysteinemia

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.